When was Cure Pharmaceutical founded?

Cure Pharmaceutical was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Cure Pharmaceutical located?

Cure Pharmaceutical is headquartered in Oxnard, United States.

How many employees does Cure Pharmaceutical have?

As of Dec 31, 2021, the latest employee count at Cure Pharmaceutical is 28.

Is Cure Pharmaceutical a funded company?

Cure Pharmaceutical is a funded company, having raised a total of $9.65M across 10 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 25, 2011.

When was the latest funding round of Cure Pharmaceutical?

Cure Pharmaceutical's latest funding was a $***** Post IPO round on Nov 02, 2020, with participation from 0 investor.

What is the annual revenue of Cure Pharmaceutical?

Annual revenue of Cure Pharmaceutical is $6.55M as on Dec 31, 2021.

Where does Cure Pharmaceutical rank among its competitors?

Cure Pharmaceutical ranks 9th amongst 59 active competitors, of which 14 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Cingulate, which secured $25M in Jul, 2025.

Who are the top competitors of Cure Pharmaceutical?

Cure Pharmaceutical's top competitors include Cingulate, Lyndra and Orbis Medicines. Among them, Cingulate secured the most recent funding round in July, 2025.

Cure Pharmaceutical - 2026 Company Profile, Funding & Competitors

Cure Pharmaceutical is a public company based in Oxnard (United States), founded in 2010. It operates as a Developer of oral thin film based drug delivery systems. Cure Pharmaceutical has raised $9.65M in funding. The company has 59 active competitors, including 14 funded and 12 that have exited. Its top competitors include companies like Cingulate, Lyndra and Orbis Medicines.

Company Details

Developer of oral thin film-based drug delivery systems. Cure Pharmaceuticals has developed several drug platform delivery systems apart from OTF, such as liquid-based encapsulation technologies, Transdermal delivery, and Gastrointestinal delivery systems. The company claims that its proprietary oral thin film technology Cure film offers greater bioavailability and transportation efficiency when compared to all conventional dosage forms such as tablets, capsules, chewable, liquids, and drops. Their proprietary transdermal drug delivery system is capable of delivering a therapeutically effective amount of drug across a patient’s skin, utilizing an epidermis penetration enhancer called a vasodilator. Their service portfolio includes process development, manufacturing, and packaging design, among others.

Website: curepharmaceutical.com
Social

Key Metrics

Founded Year

2010

Location

Oxnard, United States

Stage

Public

Total Funding

$9.65M in 10 rounds

Latest Funding Round

Post IPO, Nov 02, 2020, $*****

Investors

Onbelay Capital & 2 more

Ranked

9^th among 59 active competitors

Annual Revenue

$6.55M as on Dec 31, 2021

Employee Count

28 as on Dec 31, 2021

Investment & Acquisitions

Sera Labs & 1 more

Similar Companies

Cingulate & 57 more

Exit Details

Public

View Cure Pharmaceutical's full profile

Cure Pharmaceutical is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cure Pharmaceutical Holding Corp. CIN: 1643301 , United States, Active		$6.55M (As on Dec 31, 2021)	-	-
CURE PHARMACEUTICAL Corp CIN: 45-2717791 , United States, Active	Dec 31, 2009	$1M - $5M (As on Jul 18, 2012)	-	-

Cure Pharmaceutical got listed on Jan 20, 2017.

Click here to take a look at Cure Pharmaceutical's IPO in detail

Cure Pharmaceutical has raised a total funding of $9.65M over 10 rounds. Its first funding round was on Jul 25, 2011. Cure Pharmaceutical has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Cure Pharmaceutical:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 02, 2020	1918697	Post IPO	4700349	8728663	9689206	7642525
Feb 21, 2018	5284957	Post IPO	7864142	6695903	7275171	Gene Salkind
Oct 19, 2016	5906714	Series A	9399221	4368011	8138459	6146719

Access funding benchmarks and valuations. Sign up today!

View details of Cure Pharmaceutical's funding rounds and investors

Cure Pharmaceutical's employee count trend

Cure Pharmaceutical has 28 employees as of Dec 21. Here is Cure Pharmaceutical's employee count trend over the years:

Employee count trend for Cure Pharmaceutical

Uncover Cure Pharmaceutical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cure Pharmaceutical include Cingulate, Lyndra and Orbis Medicines. Here is the list of Top 10 competitors of Cure Pharmaceutical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cingulate 2012, Kansas City (United States), Public	Developer of therapeutics for the treatment of ADHD	$33M	The Werth Family Foundation, Lincoln Park Capital ... & 2 others	58/100
2nd	Lyndra 2015, Cambridge (United States), Deadpooled	Developer of oral drug delivery formulations	$305M	Polaris Partners, AIG & 24 others	57/100
3rd	Orbis Medicines 2022, Copenhagen (Denmark), Series A	Provider of drug discovery platform to develop multiple therapeutics	$126M	New Enterprise Associates, Forbion & 4 others	55/100
4th	PLx Pharma 2002, Sparta (United States), Public	Developer of drug delivery platform to treat gastrointestinal diseases	$25.3M	Aurus, HHS	53/100
5th	Biograil 2019, Hedehusene (Denmark), Series B	Provider of technology for oral delivery of biologics	$28.4M	Verve Ventures, Evonik & 8 others	49/100
6th	Lipocine 1997, Salt Lake City (United States), Public	Develops oral versions of hormones using Hydroance drug delivery technology	$38M	Foresite Capital	48/100
7th	OnDosis 2017, Gothenburg (Sweden), Series B	Developer of an oral drug delivery system	$14.5M	Aeternum, Astrazeneca & 7 others	47/100
8th	G2GBIO 2017, Yuseong District (South Korea), Public	Developer of sustained release injectables	-	Korea Investment Holdings, BNK Venture Capital ... & 1 others	46/100
9th	Cure Pharmaceutical 2010, Oxnard (United States), Public	Developer of oral thin film based drug delivery systems	$9.65M	Onbelay Capital, Hangar202 & 1 others	52/100
10th	Oramed 2006, Jerusalem (Israel), Public	Developer of oral reformulations to treat various health conditions	-	EIC Fund, Europa	45/100